Trade Theravance Biopharma, Inc. - TBPH CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.52 |
| Open | 8.44 |
| 1-Year Change | -12.63% |
| Day's Range | 8.44 - 8.64 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 8.56 | 0.10 | 1.18% | 8.46 | 8.64 | 8.44 |
| Apr 16, 2025 | 8.52 | 0.03 | 0.35% | 8.49 | 8.64 | 8.34 |
| Apr 15, 2025 | 8.56 | 0.03 | 0.35% | 8.53 | 8.78 | 8.45 |
| Apr 14, 2025 | 8.67 | 0.23 | 2.73% | 8.44 | 8.73 | 8.16 |
| Apr 11, 2025 | 8.36 | 0.02 | 0.24% | 8.34 | 8.38 | 8.03 |
| Apr 10, 2025 | 8.32 | 0.02 | 0.24% | 8.30 | 8.39 | 7.96 |
| Apr 9, 2025 | 8.47 | 0.49 | 6.14% | 7.98 | 8.74 | 7.98 |
| Apr 8, 2025 | 8.26 | -0.45 | -5.17% | 8.71 | 8.71 | 8.17 |
| Apr 7, 2025 | 8.38 | 0.29 | 3.58% | 8.09 | 8.54 | 7.80 |
| Apr 4, 2025 | 8.34 | -0.08 | -0.95% | 8.42 | 8.55 | 8.29 |
| Apr 3, 2025 | 8.70 | 0.02 | 0.23% | 8.68 | 8.93 | 8.61 |
| Apr 2, 2025 | 8.93 | 0.04 | 0.45% | 8.89 | 8.99 | 8.71 |
| Apr 1, 2025 | 8.96 | 0.09 | 1.01% | 8.87 | 9.02 | 8.67 |
| Mar 31, 2025 | 8.87 | -0.15 | -1.66% | 9.02 | 9.12 | 8.87 |
| Mar 28, 2025 | 9.16 | -0.01 | -0.11% | 9.17 | 9.37 | 9.13 |
| Mar 27, 2025 | 9.28 | 0.13 | 1.42% | 9.15 | 9.39 | 9.01 |
| Mar 26, 2025 | 9.28 | 0.11 | 1.20% | 9.17 | 9.35 | 9.11 |
| Mar 25, 2025 | 9.25 | -0.07 | -0.75% | 9.32 | 9.39 | 9.18 |
| Mar 24, 2025 | 9.37 | 0.04 | 0.43% | 9.33 | 9.45 | 9.29 |
| Mar 21, 2025 | 9.38 | 0.14 | 1.52% | 9.24 | 9.52 | 9.20 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Theravance Biopharma, Inc. Company profile
About Theravance Biopharma Inc
Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Theravance Biopharma Inc revenues decreased 23% to $55.3M. Net loss decreased 28% to $199.4M. Revenues reflect U.S. segment decrease of 21% to $55.3M, Europe segment decrease of 98% to $38K. Lower net loss reflects Research and development - bal decrease of 27% to $166.6M (expense), Selling, general and administrative -bal decrease of 55% to $31M (expense).
| Industry: | Pharmaceuticals (NEC) |
Ugland House, South Church Street
GEORGE TOWN
GRAND CAYMAN KY1-1104
KY
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com